Angelalign Technology (6699) H1 2026 earnings summary

Executive summary

• Achieved strong business growth in H1 2026, with global markets contributing over half of total clear aligner case volume and revenue, and reaching profitability.

• Total clear aligner case volume rose 40.2% year-over-year to 316,609; global markets (ex-China) up 43.4% and China mainland up 36.8%.

• Revenue increased 42.9% year-over-year to USD230.7 million, driven by both global and China mainland markets.

• Net profit surged 79.6% year-over-year to USD25.5 million; adjusted net profit up 79.5% to USD35.0 million.

• Years of investment in professional education, direct sales, and local service teams have delivered economies of scale and improved profitability.

Financial highlights

• Revenue: USD230.7 million (+42.9% YoY); gross profit: USD144.7 million (+43.8% YoY); gross margin: 62.7%.

• Net profit: USD25.5 million (+79.6% YoY); net profit margin: 11.0% (up from 8.8%).

• Adjusted net profit: USD35.0 million (+79.5% YoY); adjusted net profit margin: 15.2%.

• EBITDA: USD45.6 million; adjusted EBITDA: USD47.8 million.

• Interim dividend of HKD0.47 and special dividend of HKD4.10 per share declared.

Outlook and guidance

• Focus on expanding clinical capabilities for complex cases, strengthening compliance, data security, and IP protection.

• Continued investment in professional education, R&D, and global sales/service networks to drive growth.

• Management expects to capture long-term opportunities from global adoption of clear aligner treatment.

• Committed to protecting innovations and adapting to macroeconomic, regulatory, and geopolitical changes.

• Global clear aligner industry is expanding, with more complex cases and higher expectations for outcomes.